Vaccinations in Older Adults

Megan Burke, мD^{a,*}, Theresa Rowe, DO, MS^b

KEYWORDS

- Vaccinations Immunizations Older adults Immune senescence
- Pneumococcal Influenza Herpes zoster

KEY POINTS

- Older adults are at increased risk for vaccine-preventable infections. Rates of immunizations among older adults remain lower than goal despite guidelines, leaving room for intervention and improvement.
- Most of the morbidity and mortality related to vaccine-preventable illnesses in older adults in the United States is related to influenza and pneumococcal disease.
- There is a high-dose influenza vaccination specifically targeted for older adults; however, the Advisory Committee on Immunization Practices does not express preference for either high-dose or standard-dose influenza vaccine use in this population.
- Cost of immunizations influence vaccination rates in older adults.

INTRODUCTION

Vaccines are important for preventing infections in older adults aged \geq 65 years. It is estimated that more than 40,000 older adults die each year in the United States from vaccine-preventable infections, with influenza being the largest contributor.¹ Increasing the rate of vaccinations among older adults is a priority of the US government addressed in the Healthy People 2020 initiative.² Older adults are at increased risk for serious complications from vaccine-preventable illnesses due to age-associated changes in immune function, and chronic medical comorbidities, which place them at both higher risk for infection and for having an infection with a protracted course.³ Although practice guidelines are well established by the Advisory Committee on Immunization Practices (ACIP), and endorsed by most professional societies, vaccination rates for older adults remain low, with approximately 74.0% of

E-mail address: mburke31@jhmi.edu

Disclosure Statement: No disclosures.

^a Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 5200 Eastern Avenue, MFL Center Tower, Suite 2200, Baltimore, MD 21224, USA; ^b General Internal Medicine and Geriatrics, Northwestern Feinberg School of Medicine, 750 North Lakeshore Drive, 10th Floor, Chicago, IL 60611, USA * Corresponding author.

older adults receiving the influenza vaccination during the 2015 influenza season, 64.0% of older adults receiving any pneumococcal vaccination as of 2015, and only 27.9% of eligible older adults reported receiving the herpes zoster vaccine in 2014.⁴ This article focuses on the following vaccines recommended for older adults: (1) influenza; (2) pneumococcal; (3) herpes zoster; (4) tetanus, diphtheria, pertussis; and (5) hepatitis, and how cost and public misconceptions influence vaccination rates in this population.

INFLUENZA VACCINATION

Adults aged >65 years are at greater risk for serious complications from influenza compared with younger adults because of age-associated changes in immune function.³ The Centers for Disease Control and Prevention (CDC) estimated that more than 50% of influenza-associated hospitalizations and 64% of deaths during the 2015 to 2016 influenza season were in adults aged >65 years.⁵ Although vaccination is the best way to protect against influenza and is recommended by the ACIP annually in older adults,6 studies evaluating the efficacy of vaccination in this population have produced conflicting results.⁷⁻⁹ A Cochrane review from 2010 concluded that available evidence to support the efficacy of influenza vaccination in adults aged >65 years was of poor quality.¹⁰ A systematic review and meta-analysis from 2012 also concluded that evidence to assess the efficacy and effectiveness of influenza vaccination in adults aged 65 and older was inadequate.⁹ A meta-analysis using test-negative design case-control studies from 2014 did find, however, that among community-dwelling older adults aged >60, the influenza vaccine was effective against laboratory-confirmed influenza during epidemic seasons when the vaccine was matched (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.48-0.99). Additionally, vaccination was significantly effective during regional (match: OR 0.42, 95% CI 0.30-0.60; mismatch: OR 0.57, 95% CI 0.41-0.79) and widespread (match: 0.54, 95% CI 0.46-0.62; mismatch: OR 0.72, 95% CI 0.60–0.85) outbreaks.¹¹ A 2006 Cochrane review concluded that influenza vaccination was more effective in decreasing severity of disease, hospitalization, and mortality in adults aged \geq 65 residing in long-term care compared with those living in the community.¹²

High-Dose Influenza Vaccination

Several studies have shown that adults aged \geq 65 years respond less robustly to influenza vaccination (ie, produce fewer antibodies) compared with younger adults, likely a result of age-related immunosenescence.^{13,14} To improve the efficacy of the influenza vaccine in older adults, a high-dose vaccine containing 4 times the amount of antigen (60 μ g of hemagglutinin) compared with the standard-dose vaccine (15 μ g of hemagglutinin) was developed and shown to stimulate more antibody production in this population.¹³ The high-dose vaccine was approved by the Food and Drug Administration (FDA) in 2009 and was available for use in the 2010 to 2011 influenza season. A randomized controlled trial published in 2014 demonstrated that vaccination with the high-dose vaccine was 24.2% (95% CI 9.7-36.5) more effective in preventing laboratory-confirmed influenza in adults aged 265 years living in the United States compared with the standard-dose vaccination.¹⁴ However, a subsequent large retrospective study in community-dwelling adults aged >65 in the United States did not find the high-dose vaccine to be more effective than the standard-dose vaccine for protecting against hospitalization for influenza or pneumonia (risk ratio 0.98; Cl 0.68–1.40), except in a subgroup analysis of adults aged >85 years.¹⁵ A more recent Download English Version:

https://daneshyari.com/en/article/8732366

Download Persian Version:

https://daneshyari.com/article/8732366

Daneshyari.com